BridgeBio Oncology Therapeutics (BBOT) Live Share Price, Invest From India

BridgeBio Oncology Therapeutics Stock Performance

as on September 26, 2026 at 2:16 pm IST

Day's Low
Day's High
$3.89
Day's Price Range
$4.00
$3.95
1.52%
Downside
1.27%
Upside
52 Week's Low
52 Week's High
$3.89
52-Week Price Range
$14.87
$3.95
1.52%
Downside
276.46%
Upside

BridgeBio Oncology Therapeutics share price movements today

Previous Close: $3.99
Open: $4.00
Volume: 533.9K
Market Cap: $319.9M
Day's Low - High: $3.89 - $4.00
52 Week Low - High: $3.89 - $14.87

BridgeBio Oncology Therapeutics Historical Returns

1 Month Return: -57.34 %
3 Month Return: -46.62 %
1 Year Return: -66.24 %
3 Year Return: 0 %
5 Year Return: 0 %

BridgeBio Oncology Therapeutics Stock Fundamentals & Key Indicators

Check BridgeBio Oncology Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$319.9M

EPS (TTM)

-1232.82

Dividend Yield

0.00%

PE Ratio (TTM)

Industry PE ratio

-8.07

PEG Ratio

0.00004937594435115009

Return On Equity TTM

-46.90%

BridgeBio Oncology Therapeutics Stock Valuation

Track how BridgeBio Oncology Therapeutics P/E has moved over time to understand its valuation trends.

BridgeBio Oncology Therapeutics in the last 5 years

Overview
Trends

Lowest (-59301.75x)

December 31, 2022

Industry (-8.07x)

December 31, 2025

Today (-2.91x)

December 31, 2025

Highest (-2.35x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -2.91x

BridgeBio Oncology Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BridgeBio Oncology Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
BridgeBio Oncology Therapeutics	StrongBuy	$319.9M	NA	NA	0.00%	0.00%
Moderna	Neutral	$77.8B	-53.76%	-24.41	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$132.4B	186.58%	30.16	86.04%	0.00%
Regeneron	Buy	$82.8B	23.34%	19.01	84.86%	0.46%

Stock Returns calculator for BridgeBio Oncology Therapeutics Stock including INR - Dollar returns

The BridgeBio Oncology Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

BridgeBio Oncology Therapeutics investment value today

Current value as on today

₹36,480

Returns

-₹63,520

(-63.52%)

Returns from BridgeBio Oncology Therapeutics Stock

-₹66,239 (-66.24%)

Dollar Impact

₹2,719 (+2.72%)

Analyst Recommendation on BridgeBio Oncology Therapeutics Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for BridgeBio Oncology Therapeutics. Average target price of $20.2

Indian Investors' Interest in BridgeBio Oncology Therapeutics Stock

Search interest for BridgeBio Oncology Therapeutics Stock has increased by 150% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 28, 2026 to September 27, 2026

Change:150% versus previous 30 day period

BridgeBio Oncology Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	0	-
Operating Income	-15	-23	-19	-21	-23	-30	-49	-43	-46	-60
EBITDA	-15	-23	-19	-21	-23	-29	-49	-43	-45	-56
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-15	-21	-17	-19	-22	-28	-44	-38	-42	-56
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-15	-21	-17	-19	-22	-28	-44	-38	-42	-56
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Income	0	0	0	-64	-80	-145
EBITDA	0	0	0	-64	-80	-145
Interest Expense	-	-	-	-	-	-
Depreciation	0	-	0	0	0	0
Income Before Tax	0	0	0	-64	-74	-134
Income Tax Expense	-	-	-	-	-	-
Net Income	0	0	0	-64	-74	-134
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-15	2	-17	1	0	-28	-44	-38	-42	-56
Operating Cash Flow	-8	0	-39	0	0	-23	-70	-42	-35	-44
Investing Cash Flow	2	-	37	-	-	9	65	7	-285	45
Financing Cash Flow	6	-	19	-	-	18	383	0	0	0
Change in Cash	0	0	0	0	0	5	408	-35	-321	1

BridgeBio Oncology Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	0	0	0	-64	7	-134
Operating Cash Flow	0	-	-	-52	0	-113
Investing Cash Flow	-115	-	-	-2	-184	73
Financing Cash Flow	116	-	-	55	186	383
Change in Cash	1	-	-	0	1	342

Mutual Funds that own BridgeBio Oncology Therapeutics Stock

Check out the Mutual Funds with significant holdings in BridgeBio Oncology Therapeutics.

Funds	Holdings	Shares Held
BlackRock Funds	0.840376%	673766
VANGUARD INDEX FUNDS	0.671099%	538049
Fidelity Concord Street Trust	0.626923%	502631
T. ROWE PRICE HEALTH SCIENCES FUND, INC.	0.41595%	333485
ROYCE FUND	0.311213%	249513

See all

Global Institutional Holdings in BridgeBio Oncology Therapeutics

Funds	Holdings
James E. Flynn	6.09%
Otello Stampacchia	4.1%
Vanguard	2.47%
Dennis J Purcell	1.27%
SPDR	0.85%

See all

Insights on BridgeBio Oncology Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 712.1% return, outperforming this stock by 778.3%
NEGATIVE IMPACT
Price Dip
In the last 7 days, BBOT stock has moved down by -17.2%

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Organisation	BridgeBio Oncology Therapeutics
Headquarters	256 E. Grand Avenue, South San Francisco, CA, 94080, US
Industry	Biotechnology
CEO	Pedro J. Beltran
E-voting on shares	Click here to vote

Key Management of BridgeBio Oncology Therapeutics

Name	Title
Dr. Pedro J. Beltran M.D., Ph.D.	Chief Executive Officer and Director
Mr. Marc Cobo	VP of Finance & Controller
Mr. Bin Wang Ph.D.	Senior Vice President of Drug Discovery
Mr. Rui Xu Ph.D.	Senior Vice President of Drug Discovery
Mr. Aaron Chan J.D.	Vice President of Legal
Mr. Daniel Watson Ph.D.	Senior Vice President of Chemistry, Manufacturing & Controls
Dr. Neil Kumar Ph.D.	Executive Chairman
Dr. Frank P. McCormick Ph.D.	Co-Founder, Non-Executive Director & Chair of the Advisory Board
Dr. Yong Ben M.B.A., M.D.	Chief Medical & Development Officer
Mr. Idan Elmelech M.A., M.B.A.	Chief Operating Officer

FAQs

What is BridgeBio Oncology Therapeutics share price today?

BridgeBio Oncology Therapeutics share price today is $3.95 as on September 26, 2026 at 8:46 am IST at the close of the market. BridgeBio Oncology Therapeutics share today touched a day high of $4.00 and a low of $3.89.

What is the 52 week high and 52 week low for BridgeBio Oncology Therapeutics share?

BridgeBio Oncology Therapeutics share touched a 52 week high of $14.87 on December 8, 2025 and a 52 week low of $3.89 on September 25, 2026. BridgeBio Oncology Therapeutics stock price today i.e. September 26, 2026 at 8:46 am IST is closed at $3.95,which is 73.44% down from its 52 week high and 1.54% up from its 52 week low.

What is BridgeBio Oncology Therapeutics's market capitalisation today?

BridgeBio Oncology Therapeutics market capitalisation is $0.00T as on September 26, 2026 at 8:46 am IST.

How to invest in BridgeBio Oncology Therapeutics Stock (BBOT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for BridgeBio Oncology Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in BridgeBio Oncology Therapeutics Shares that will get you 0.3797 shares as per BridgeBio Oncology Therapeutics share price of $3.95 per share as on September 26, 2026 at 8:46 am IST.

What is the minimum amount required to buy BridgeBio Oncology Therapeutics Stock (BBOT) from India?

Indian investors can start investing in BridgeBio Oncology Therapeutics (BBOT) shares with as little as ₹95.819999694824 or $1 (as of September 27, 2026 at 3:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹958.20 in BridgeBio Oncology Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 27, 2026 at 3:42 pm IST). Based on BridgeBio Oncology Therapeutics share’s latest price of $3.95 as on September 26, 2026 at 8:46 am IST, you will get 2.5316 shares of BridgeBio Oncology Therapeutics. Learn more about fractional shares .